伊阿鲁单抗治疗干燥综合征的安全性与疗效:随机、安慰剂对照、2b期剂量探索研究52周结果
这项2b期剂量探索研究将190例干燥综合征患者随机分配至伊阿鲁单抗5、50、300 mg或安慰剂组,每4周皮下给药至第24周;第24周时300 mg组再随机分为继续300 mg或安慰剂至第52周。继续300 mg至第52周的患者疗效持续,安全性良好。
要点
- 第1治疗期共随机190例:安慰剂49例、5 mg 47例、50 mg 47例、300 mg 47例。
- 继续300 mg至第52周的患者EULAR Sjögren's综合征疾病活动指数等疗效指标较第24周持续改善。
- 治疗中出现的不良事件除注射部位反应外无剂量依赖性;随访中3例出现中性粒细胞计数下降。
核心结论
- 在干燥综合征患者中,伊阿鲁单抗300 mg至第52周显示持续疗效,随访长达两年安全性良好。
研究设计与样本
- 随机、安慰剂对照、2b期剂量探索研究,患者按1:1:1:1随机接受伊阿鲁单抗5、50、300 mg或安慰剂皮下注射,每4周一次至第24周(第1治疗期)。
- 第24周时300 mg组再随机分为继续300 mg或安慰剂至第52周(第2治疗期),安慰剂组转换为伊阿鲁单抗150 mg,5和50 mg组直接进入治疗后安全性随访。
- 第1治疗期共随机190例:安慰剂49例、5 mg 47例、50 mg 47例、300 mg 47例;其中90例(47.4%)进入第2治疗期(继续300 mg 43例、安慰剂47例),90例中81例(90.0%)完成研究治疗。
主要发现
- 第2治疗期继续300 mg的患者至第52周疗效持续:EULAR Sjögren's综合征疾病活动指数、EULAR Sjögren's综合征患者报告指数、患者总体评估和医生总体评估自第24周的变化分别为-1.45、-0.46、-4.69和-6.86。
- 300 mg组刺激唾液流率和自身抗体水平呈数值改善。
- 治疗中出现的不良事件除注射部位反应外无剂量依赖性。
- 治疗后随访中3例患者出现中性粒细胞计数下降(常见不良事件术语标准v4.03版3级,依据实验室检查列表),分别发生于末次伊阿鲁单抗给药后3.5、5.5和3个月。
- 除1例无症状巨细胞病毒感染的偶然发现(IgM阳性)外,中性粒细胞计数下降均未伴随感染。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to report 52-week safety and efficacy of ianalumab from phase 2b dose-finding study in patients with Sjögren's disease (SjD). METHODS: Patients randomly received (1:1:1:1) ianalumab (5, 50, or 300 mg) or placebo subcutaneously every 4 weeks until week 24 (treatment period [TP]1). At week 24, patients on 300 mg were rerandomized to continue 300 mg or receive placebo until week 52 (TP2), patients on placebo were switched to ianalumab 150 mg, and patients on 5 and 50 mg directly entered posttreatment safety follow-up. Patients who discontinued treatment early or completed treatment entered safety follow-up (≥20 weeks). RESULTS: During TP1, 190 patients were randomized (placebo = 49, 5 mg = 47, 50 mg = 47, 300 mg = 47). Of these 190 patients, 90 (47.4 %; 43 continued 300 mg and 47 received placebo) entered TP2, and 81 of 90 (90.0%) completed the study treatment. By week 52, efficacy was sustained in patients who continued 300 mg in TP2 (EULAR Sjögren's Syndrome Disease Activity Index, EULAR Sjögren's Syndrome Patient Reported Index, patient global assessment, and physician global assessment change from week 24: -1.45, -0.46, -4.69, and -6.86, respectively). Stimulated salivary flow rates and autoantibody levels numerically improved in the 300 mg group. Treatment-emergent adverse events were not dose-dependent, except for injection-site reactions. Cases of decreased neutrophil counts (Common Terminology Criteria for Adverse Events v4.03 grade 3 according to laboratory listings) were observed in three patients during the posttreatment follow-up, occurring at 3.5, 5.5, and 3 months, after the last ianalumab administration. None were associated with infection except one incidental finding of asymptomatic cytomegalovirus infection (IgM-positive). CONCLUSION: In patients with SjD, ianalumab 300 mg demonstrated sustained efficacy through week 52 and a favorable safety profile up to two years of follow-up.
引用
- Dörner T, Bowman SJ, Fox R, et al. Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study. Arthritis Rheumatol. 2025. PMID: 39557617. doi:10.1002/art.43059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。